Personalis Inc (04X)
XBER 
Summary
04X Chart
Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)
The heavy selling pressure might have exhausted for Personalis (PSNL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)
Personalis (PSNL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy
Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Personalis Inc Dividends
Personalis Inc Earnings
| 5 Nov 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
| 4 Nov 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
| 4 Nov 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 Date | | - Cons. EPS | - EPS |
Personalis Inc (04X) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Personalis Inc ever had a stock split?
Personalis Inc Profile
| Medical - Diagnostics & Research Industry | Healthcare Sector | Christopher M. Hall CEO | XBER Exchange | US71535D1063 ISIN |
| US Country | 228 Employees | - Last Dividend | - Last Split | 20 Jun 2019 IPO Date |
Overview
Personalis, Inc. is a biotechnology firm, established in 2011 with its headquarters in Fremont, California, that specializes in the development and marketing of innovative cancer genomic tests and analytics. The company serves a broad international market, including regions such as the United States, Europe, and the Asia-Pacific. Personalis caters to the needs of pharmaceutical companies for translational research and biomarker discovery, aiding the development of personalized cancer therapies. Moreover, it provides sophisticated tests employed by physicians to identify cancer recurrence, monitor the evolution of the disease, and discover vital information for choosing appropriate therapy options. Its clientele encompasses pharmaceutical and biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and individual patients.
Products and Services
- NeXT Personal
- ImmunoID NeXT
- NeXT Personal Dx
- NeXT Dx
- Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS)
This is a tumor-informed liquid biopsy test designed for the detection of minimal residual disease (MRD) and the recurrence of cancer. It enables personalized monitoring and treatment options by providing a deep insight into the molecular signature of an individual's cancer.
A tissue-based comprehensive test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data. Through advanced analytics, it offers a multi-dimensional view of the tumor and its microenvironment from a single sample, facilitating the development of targeted cancer therapies and immunotherapies.
Similar to NeXT Personal, this test offers tumor-informed liquid biopsy capabilities for the detection of MRD and cancer recurrence, specifically designed with a diagnostic focus to aid clinicians in the personalized treatment of cancer patients.
A comprehensive tumor profiling test that unlocks insights into the entire exome (DNA) and transcriptome (RNA) of a cancer patient. By providing matched tumor-normal analysis, it leverages detailed genomic information to better understand the disease and guide treatment options.
Personalis offers WES of cancer tissue and matched blood samples, and WGS on human samples for a variety of purposes including diagnostic tool development, research projects, and population sequencing initiatives. These services are complemented by the company’s sequencing and data analysis capabilities, supporting the broader research and medical community in uncovering new insights into cancer genomics.
Contact Information
